|
1
|
National Cancer Center Japan, Center for
Cancer Control and Information Services. 2020, https://ganjoho.jp/reg_stat/statistics/stat/summary.html
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rawla P, Sunkara T and Gaduputi V:
Epidemiology of pancreatic cancer: Global trends, etiology and risk
factors. World J Oncol. 10:10–27. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cao H, Le D and Yang LX: Current status in
chemotherapy for advanced pancreatic adenocarcinoma. Anticancer
Res. 33:1785–1791. 2013.PubMed/NCBI
|
|
5
|
Conroy T, Desseigne F, Ychou M, Bouché O,
Guimbaud R, Bécouarn Y, Adenis A, Raoul J, Gourgou-Bourgade S, de
la Fouchardière C, et al: FOLFIRINOX versus gemcitabine for
metastatic pancreatic cancer. N Engl J Med. 364:1817–1825. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Von Hoff DD, Ervin T, Arena FP, hiorean
EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et
al: Increased survival in pancreatic cancer with nab-paclitaxel
plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Torphy RJ, Fujiwara Y and Schulick RD:
Pancreatic cancer treatment: Better, but a long way to go. Surg
Today. 50:1117–1125. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang Z, Dabrosin C, Yin X, Fuster MM,
Arreola A, Rathmell WK, Generali D, Nagaraju GP, El-Rayes B,
Ribatti D, et al: Broad targeting of angiogenesis for cancer
prevention and therapy. Semin Cancer Biol. 35 (Suppl 1):S224–S243.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gupta SC, Kim JH, Prasad S and Aggarwal
BB: Regulation of survival, proliferation, invasion, angiogenesis,
and metastasis of tumor cells through modulation of inflammatory
pathways by nutraceuticals. Cancer Metastasis Rev. 29:405–434.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kwak H, An H, Alam MB, Choi WS, Lee SY and
Lee SH: Inhibition of migration and invasion in melanoma cells by
β-escin via the ERK/NF-κB signaling pathway. Biol Pharm Bull.
41:1606–1610. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Çiftçi GA, Işcan A and Kutlu M: Escin
reduces cell proliferation and induces apoptosis on glioma and lung
adenocarcinoma cell lines. Cytotechnology. 67:893–904. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Harford-Wright E, Bidère N and Gavard J:
β-escin selectively targets the glioblastoma-initiating cell
population and reduces cell viability. Oncotarget. 7:66865–66879.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rimmon A, Vexler A, Berkovich L, Earon G,
Ron I and Lev-Ari S: Escin chemosensitizes human pancreatic cancer
cells and inhibits the nuclear factor-kappaB signaling pathway.
Biochem Res Int. 2013:2517522013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhu J, Yu W, Liu B, Wang Y, Shao J, Wang
J, Xia K, Liang C, Fang W, Zhou C and Tao H: Escin induces
caspase-dependent apoptosis and autophagy through the ROS/p38 MAPK
signalling pathway in human osteosarcoma cells in vitro and in
vivo. Cell Death Dis. 8:e31132017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang YW, Wang SJ, Zhou YN, Pan SH and Sun
B: Escin augments the efficacy of gemcitabine through
down-regulation of nuclear factor-κB and nuclear
factor-κB-regulated gene products in pancreatic cancer both in
vitro and in vivo. J Cancer Res Clin Oncol. 138:785–797. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Harikumar KB, Sung B, Pandey MK, Guha S,
Krishnan S and Aggarwal BB: Escin, a pentacyclic triterpene,
chemosensitizes human tumor cells through inhibition of nuclear
factor-kappaB signaling pathway. Mol Pharmacol. 77:818–827. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pramanik K, Makena M, Bhowmick K and
Pandey M: Advancement of NF-κB signaling pathway: A novel target in
pancreatic cancer. Int J Mol Sci. 19:38902018. View Article : Google Scholar
|
|
18
|
Matsuo Y, Sawai H, Ochi N, Yasuda A,
Sakamoto M, Takahashi H, Funahashi H, Takeyama H and Guha S:
Proteasome inhibitor MG132 inhibits angiogenesis in pancreatic
cancer by blocking NF-kappaB activity. Dig Dis Sci. 55:1167–1176.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bussolino F, Mantovani A and Persico G:
Molecular mechanisms of blood vessel formation. Trends Biochem Sci.
22:251–256. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sosmitha G, Bano S, Javadi M, Lu F,
Clarissa EH, Frank A, Kwang Seok A, Gautam S and Ajaikumar BK:
Zerumbone as an anti-cancer agent. Molecules. 24:7342019.
View Article : Google Scholar
|
|
21
|
Meteoglu I, Erdogdu IH, Meydan N, Erkus M
and Barutca S: NF-KappaB expression correlates with apoptosis and
angiogenesis in clear cell renal cell carcinoma tissues. J Exp Clin
Cancer Res. 27:532008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Itakura J, Ishiwata T, Friess H, Fujii H,
Matsumoto Y, Büchler MW and Korc M: Enhanced expression of vascular
endothelial growth factor in human pancreatic cancer correlates
with local disease progression. Clin Cancer Res. 3:1309–1316.
1997.PubMed/NCBI
|
|
23
|
Shi Q, Abbruzzese JL, Huang S, Fidler IJ,
Xiong Q and Xie K: Constitutive and inducible interleukin 8
expression by hypoxia and acidosis renders human pancreatic cancer
cells more tumorigenic and metastatic. Clin Cancer Res.
5:3711–3721. 1999.PubMed/NCBI
|
|
24
|
Shi Q, Le X, Abbruzzese JL, Peng Z, Qian
CN, Tang H, Xiong Q, Wang B, Li XC and Xie K: Constitutive Sp1
activity is essential for differential constitutive expression of
vascular endothelial growth factor in human pancreatic
adenocarcinoma. Cancer Res. 61:4143–4154. 2001.PubMed/NCBI
|
|
25
|
Saito K, Matsuo Y, Imafuji H, Okubo T,
Maeda Y, Sato T, Shamoto T, Tsuboi K, Morimoto M, Takahashi H, et
al: Xanthohumol inhibits angiogenesis by suppressing nuclear
factor-κB activation in pancreatic cancer. Cancer Sci. 109:132–140.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tsuboi K, Matsuo Y, Shamoto T, Shibata T,
Koide S, Morimoto M, Guha S, Sung B, Aggarwal BB, Takahashi H and
Takeyama H: Zerumbone inhibits tumor angiogenesis via NF-κB in
gastric cancer. Oncol Rep. 31:57–64. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bustin S: Quantification of mRNA using
real-time reverse transcription PCR (RT-PCR): Trends and problems.
J Mol Endocrinol. 29:23–39. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Folkman J: Angiogenesis and angiogenesis
inhibition: An overview. Exs. 79:1–8. 1997.PubMed/NCBI
|
|
29
|
Brown LF, Berse B, Jackman RW, Tognazzi K,
Manseau EJ, Senger DR and Dvorak HF: Expression of vascular
permeability factor (vascular endothelial growth factor) and its
receptors in adenocarcinomas of the gastrointestinal tract. Cancer
Res. 53:4727–4735. 1993.PubMed/NCBI
|
|
30
|
Sawai H, Funahashi H, Okada Y, Matsuo Y,
Sakamoto M, Yamamoto M, Takeyama H and Manabe T: Interleukin-1alpha
enhances IL-8 secretion through p38 mitogen-activated protein
kinase and reactive oxygen species signaling in human pancreatic
cancer cells. Med Sci Monit. 11:BR343–BR350. 2005.PubMed/NCBI
|
|
31
|
Aggarwal BB: Nuclear factor-kappaB: The
enemy within. Cancer Cell. 6:203–208. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Xiong HQ, Abbruzzese JL, Lin E, Wang L,
Zheng L and Xie K: NF-kappaB activity blockade impairs the
angiogenic potential of human pancreatic cancer cells. Int J
Cancer. 108:181–188. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Arlt A and Schäfer H: NFkappaB-dependent
chemoresistance in solid tumors. Int J Clin Pharmacol Ther.
40:336–347. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sebens S, Arlt A and Schäfer H: NF-kappaB
as a molecular target in the therapy of pancreatic carcinoma.
Recent Results Cancer Res. 177:151–164. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Holcomb B, Yip-Schneider M and Schmidt CM:
The role of nuclear factor kappaB in pancreatic cancer and the
clinical applications of targeted therapy. Pancreas. 36:225–235.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen D, Frezza M, Schmitt S, Kanwar J and
Dou QP: Bortezomib as the first proteasome inhibitor anticancer
drug: Current status and future perspectives. Curr Cancer Drug
Targets. 11:239–253. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Aggarwal BB, Van Kuiken ME, Iyer LH,
Harikumar KB and Sung B: Molecular targets of nutraceuticals
derived from dietary spices: Potential role in suppression of
inflammation and tumorigenesis. Exp Biol Med (Maywood).
234:825–849. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Harikumar KB, Sung B, Tharakan ST, Pandey
MK, Joy B, Guha S, Krishnan S and Aggarwal BB: Sesamin manifests
chemopreventive effects through the suppression of
NF-kappaB-regulated cell survival, proliferation, invasion, and
angiogenic gene products. Mol Cancer Res. 8:751–761. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yue Q, Gao G, Zou G, Yu H and Zheng X:
Natural products as adjunctive treatment for pancreatic cancer:
Recent trends and advancements. Biomed Res Int. 2017:84125082017.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kunnumakkara AB, Guha S, Krishnan S,
Diagaradjane P, Gelovani J and Aggarwal BB: Curcumin potentiates
antitumor activity of gemcitabine in an orthotopic model of
pancreatic cancer through suppression of proliferation,
angiogenesis, and inhibition of nuclear factor-kappaB-regulated
gene products. Cancer Res. 67:3853–3861. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Gallelli L: Escin: A review of its
anti-edematous, anti-inflammatory, and venotonic properties. Drug
Des Devel Ther. 13:3425–3437. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Li M, Lu C, Zhang L, Zhang J, Du Y, Duan
S, Wang T and Fu F: Oral administration of escin inhibits acute
inflammation and reduces intestinal mucosal injury in animal
models. Evid Based Complement Alternat Med.
2015:5036172015.PubMed/NCBI
|
|
43
|
Trauzold A, Röder C, Sipos B, Karsten K,
Arlt A, Jiang P, Martin-Subero JI, Siegmund D, Müerköster S,
Pagerols-Raluy L, et al: CD95 and TRAF2 promote invasiveness of
pancreatic cancer cells. FASEB J. 19:620–622. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Sclabas GM, Fujioka S, Schmidt C, Li Z,
Frederick WA, Yang W, Yokoi K, Evans DB, Abbruzzese JL, Hess KR, et
al: Overexpression of tropomysin-related kinase B in metastatic
human pancreatic cancer cells. Clin Cancer Res. 11:440–449.
2005.PubMed/NCBI
|
|
45
|
Stipa F, Lucandri G, Limiti MR, Bartolucci
P, Cavallini M, Di Carlo V, D'Amato A, Ribotta G and Stipa S:
Angiogenesis as a prognostic indicator in pancreatic ductal
adenocarcinoma. Anticancer Res. 22:445–449. 2002.PubMed/NCBI
|
|
46
|
Benckert C, Thelen A, Cramer T, Weichert
W, Gaebelein G, Gessner R and Jonas S: Impact of microvessel
density on lymph node metastasis and survival after curative
resection of pancreatic cancer. Surg Today. 42:169–176. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Amin Z, Theis B, Russell RC, House C,
Novelli M and Lees WR: Diagnosing pancreatic cancer: The role of
percutaneous biopsy and CT. Clin Radiol. 61:996–1002. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Annese T, Tamma R, Ruggieri S and Ribatti
D: Angiogenesis in pancreatic cancer: Pre-clinical and clinical
studies. Cancers (Basel). 11:3812019. View Article : Google Scholar
|
|
49
|
Zhang Z, Ji S, Zhang B, Liu J, Qin Y, Xu J
and Yu X: Role of angiogenesis in pancreatic cancer biology and
therapy. Biomed Pharmacother. 108:1135–1140. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Matsuo Y, Raimondo M, Woodward TA, Wallace
MB, Gill RA, Tong Z, Burdick MD, Yang Z, Strieter RM, Hoffman RM
and Guha S: CXC-chemokine/CXCR2 biological axis promotes
angiogenesis in vitro and in vivo in pancreatic cancer. Int J
Cancer. 125:1027–1037. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Yang HL, Chang HC, Lin SW, Kumar KJS, Liao
CH, Wang HM, Lin KY and Hseu YC: Antrodia salmonea inhibits
TNF-α-induced angiogenesis and atherogenesis in human endothelial
cells through the down-regulation of NF-κB and up-regulation of
Nrf2 signaling pathways. J Ethnopharmacol. 151:394–406. 2014.
View Article : Google Scholar : PubMed/NCBI
|
